Cellectis to Report Q2 2025 Financial Results on August 4, 2025
PorAinvest
lunes, 28 de julio de 2025, 4:33 pm ET1 min de lectura
CLLS--
Cellectis, a clinical-stage biotechnology company, utilizes its pioneering gene-editing platform TALEN® to develop life-saving cell and gene therapies. The company focuses on allogeneic CAR T immunotherapies in oncology and pioneers the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells for cancer treatment [1][2]. Cellectis also has a platform for developing gene therapies in other therapeutic indications, thanks to its in-house manufacturing capabilities, which allow it to control the cell and gene therapy value chain from start to finish [1][2].
Investors and financial professionals can access the conference call through domestic (+1-800-343-5172) or international (+1-203-518-9856) dial-in numbers using Conference ID: CLLSQ2 [1][2]. The webcast link is available at https://viavid.webcasts.com/starthere.jsp?ei=1727030&tp_key=10a62ee950 [1][2].
Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and Euronext Growth (ticker: ALCLS) [1][2]. For further information on Cellectis, please visit www.cellectis.com or contact media@cellectis.com [1].
References:
[1] https://www.globenewswire.com/news-release/2025/07/28/3122870/0/fr/Cellectis-publiera-ses-r%C3%A9sultats-financiers-du-deuxi%C3%A8me-trimestre-2025-le-4-ao%C3%BBt-2025.html
[2] https://www.stocktitan.net/news/CLLS/cellectis-to-report-second-quarter-2025-financial-results-on-august-fsw0vxzd4znb.html
Cellectis, a clinical-stage biotechnology company, will report its Q2 2025 financial results on August 4, 2025. The company will hold a conference call on August 5, 2025 at 14:00 CET / 8:00 AM ET to discuss the results and update on its activities. The call will be available via phone and webcast.
Paris-based biotechnology company Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS) has announced that it will publish its financial results for the second quarter ending June 30, 2025, on August 4, 2025, after the close of the U.S. market [1]. The company will also hold an investor conference call and webcast on August 5, 2025, at 14:00 CET / 8:00 AM ET to discuss the Q2 results and provide an update on its business activities [1].Cellectis, a clinical-stage biotechnology company, utilizes its pioneering gene-editing platform TALEN® to develop life-saving cell and gene therapies. The company focuses on allogeneic CAR T immunotherapies in oncology and pioneers the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells for cancer treatment [1][2]. Cellectis also has a platform for developing gene therapies in other therapeutic indications, thanks to its in-house manufacturing capabilities, which allow it to control the cell and gene therapy value chain from start to finish [1][2].
Investors and financial professionals can access the conference call through domestic (+1-800-343-5172) or international (+1-203-518-9856) dial-in numbers using Conference ID: CLLSQ2 [1][2]. The webcast link is available at https://viavid.webcasts.com/starthere.jsp?ei=1727030&tp_key=10a62ee950 [1][2].
Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and Euronext Growth (ticker: ALCLS) [1][2]. For further information on Cellectis, please visit www.cellectis.com or contact media@cellectis.com [1].
References:
[1] https://www.globenewswire.com/news-release/2025/07/28/3122870/0/fr/Cellectis-publiera-ses-r%C3%A9sultats-financiers-du-deuxi%C3%A8me-trimestre-2025-le-4-ao%C3%BBt-2025.html
[2] https://www.stocktitan.net/news/CLLS/cellectis-to-report-second-quarter-2025-financial-results-on-august-fsw0vxzd4znb.html

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios